Literature DB >> 24934488

Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception.

Lauren N C Johnson1, Mary D Sammel2, Katherine E Dillon3, Lara Lechtenberg3, Allison Schanne3, Clarisa R Gracia3.   

Abstract

OBJECTIVE: To determine the impact of hormonal contraception (HC) on markers of ovarian reserve, including antimüllerian hormone (AMH) and antral follicle count (AFC).
DESIGN: Longitudinal prospective cohort.
SETTING: University hospital. PATIENT(S): Young adult female cancer survivors and healthy similar-age women. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Participants were followed annually to determine hormone levels and for transvaginal ultrasound. Subjects who used HC within the preceding 3 months were considered to be exposed. Linear mixed effects models were used to incorporate repeated measures and adjust for potential confounders. RESULT(S): A total of 249 women (126 survivors, 123 control subjects; average age 25.5 years) were followed for an average of 2.1 visits and 2.15 years. After adjusting for confounders, AMH was found to be 21% lower among survivors using HC and 55% lower among control subjects using HC (relative risk [RR] 0.79, 95% confidence interval [CI] 0.68-0.93; and RR 0.45, 95% CI 0.30-0.68; respectively). AFC was 20% lower among survivors and control subjects using HC (RR 0.80, 95% CI 0.69-0.93). When considering an individual subject, AMH was 17%-35% lower when a subject had recently used HC than when she had not (survivors: RR 0.83, 95% CI 0.75-0.93; control subjects: RR 0.65, 95% CI 0.55-0.78), and AFC was 11% lower (RR 0.89, 95% CI 0.82-0.96). Additive HC exposure across multiple visits was not associated with differences in AMH or AFC. CONCLUSION(S): AMH and AFC are significantly lower among women with recent exposure to HC. AMH and AFC should be interpreted with caution when measured in the setting of recent hormone use.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contraception; antimüllerian hormone; antral follicle count; birth control; cancer; ovarian reserve

Mesh:

Substances:

Year:  2014        PMID: 24934488      PMCID: PMC4149933          DOI: 10.1016/j.fertnstert.2014.05.026

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  26 in total

1.  Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve.

Authors:  I A J van Rooij; F J M Broekmans; E R te Velde; B C J M Fauser; L F J M M Bancsi; F H de Jong; A P N Themmen
Journal:  Hum Reprod       Date:  2002-12       Impact factor: 6.918

2.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

3.  Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome.

Authors:  Asli Somunkiran; Tevfik Yavuz; Oguz Yucel; Ismail Ozdemir
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-03-01       Impact factor: 2.435

4.  Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level.

Authors:  Dave J Hendriks; Ben-Willem J Mol; László F J M M Bancsi; Egbert R Te Velde; Frank J M Broekmans
Journal:  Fertil Steril       Date:  2005-02       Impact factor: 7.329

5.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.

Authors:  David B Seifer; David T MacLaughlin; Benjamin P Christian; Bo Feng; Robert M Shelden
Journal:  Fertil Steril       Date:  2002-03       Impact factor: 7.329

6.  Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.

Authors:  MaryFran Sowers; Daniel McConnell; Katherine Gast; Huiyong Zheng; Bin Nan; Jenifer D McCarthy; John F Randolph
Journal:  Fertil Steril       Date:  2009-12-06       Impact factor: 7.329

7.  Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve.

Authors:  Janet Kwee; Roel Schats; Joseph McDonnell; Axel Themmen; Frank de Jong; Cornelis Lambalk
Journal:  Fertil Steril       Date:  2007-10-17       Impact factor: 7.329

8.  Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids.

Authors:  Isabelle Streuli; Timothée Fraisse; Christine Pillet; Victoria Ibecheole; Paul Bischof; Dominique de Ziegler
Journal:  Fertil Steril       Date:  2007-10-24       Impact factor: 7.329

Review 9.  The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count.

Authors:  Simone L Broer; Ben Willem J Mol; Dave Hendriks; Frank J M Broekmans
Journal:  Fertil Steril       Date:  2008-03-05       Impact factor: 7.329

10.  Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women.

Authors:  Dorothea M Wunder; Nick A Bersinger; Mengistu Yared; Robert Kretschmer; Martin H Birkhäuser
Journal:  Fertil Steril       Date:  2007-07-02       Impact factor: 7.329

View more
  9 in total

1.  Antimüllerian hormone levels are lower in BRCA2 mutation carriers.

Authors:  Lauren Johnson; Mary D Sammel; Susan Domchek; Allison Schanne; Maureen Prewitt; Clarisa Gracia
Journal:  Fertil Steril       Date:  2017-05       Impact factor: 7.329

2.  Chemotherapy-related damage to ovarian reserve in childhood cancer survivors: interpreting the evidence.

Authors:  Edgardo Somigliana; Monica Terenziani; Francesca Filippi; Alice Bergamini; Fabio Martinelli; Giorgia Mangili; Fedro Peccatori; Paolo Vercellini
Journal:  J Assist Reprod Genet       Date:  2018-10-25       Impact factor: 3.412

3.  Outcomes of ovarian stimulation after treatment with chemotherapy.

Authors:  Jessica L Chan; Lauren N C Johnson; Brenda L Efymow; Mary D Sammel; Clarisa R Gracia
Journal:  J Assist Reprod Genet       Date:  2015-09-23       Impact factor: 3.412

4.  Outdoor air pollution and anti-Müllerian hormone concentrations in the Sister Study.

Authors:  Allyson M Gregoire; Kristen Upson; Nicole M Niehoff; Helen B Chin; Joel D Kaufman; Clarice R Weinberg; Dale P Sandler; Hazel B Nichols; Alexandra J White
Journal:  Environ Epidemiol       Date:  2021-08-16

5.  The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis.

Authors:  Wei-Wei Yin; Chang-Chang Huang; Yi-Ru Chen; Dan-Qing Yu; Min Jin; Chun Feng
Journal:  BMC Endocr Disord       Date:  2022-06-14       Impact factor: 3.263

Review 6.  Fertility after Cancer: Risks and Successes.

Authors:  Chiara Di Tucci; Giulia Galati; Giulia Mattei; Alessandra Chinè; Alice Fracassi; Ludovico Muzii
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

7.  Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies.

Authors:  Jovana Lekovich; Alexandre L S Lobel; Joshua D Stewart; Nigel Pereira; Isaac Kligman; Zev Rosenwaks
Journal:  J Assist Reprod Genet       Date:  2016-03-04       Impact factor: 3.412

8.  Duration, recency, and type of hormonal contraceptive use and antimüllerian hormone levels.

Authors:  Lia A Bernardi; Marissa Steinberg Weiss; Anne Waldo; Quaker Harmon; Mercedes R Carnethon; Donna D Baird; Lauren A Wise; Erica E Marsh
Journal:  Fertil Steril       Date:  2021-03-19       Impact factor: 7.490

9.  Decline of ovarian function in patients with rheumatoid arthritis: serum anti-Müllerian hormone levels in a longitudinal cohort.

Authors:  Jenny Brouwer; Radboud J E M Dolhain; Johanna M W Hazes; Nicole S Erler; Jenny A Visser; Joop S E Laven
Journal:  RMD Open       Date:  2020-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.